You are here

  • Home
  • Archive
  • Volume 13, Issue 5
  • Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab

Article metrics

Article menu
Download PDFPDF
Colorectal
Original research
Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab

 

Online download statistics by month:

Online download statistics by month: January 2022 to March 2024

AbstractFullPdf
Jan 202210247349
Feb 2022600617
Mar 20222491211
Apr 2022138210
May 202212346
Jun 202211585
Jul 20226485
Aug 20224873927
Sep 20227857247
Oct 20223252724
Nov 20221931411
Dec 20222361614
Jan 2023197155
Feb 2023197148
Mar 20232792212
Apr 20233041913
May 2023249125
Jun 202312823
Jul 202311795
Aug 202313484
Sep 202313855
Oct 202311474
Nov 2023134112
Dec 202312752
Jan 202416232
Feb 202411135
Mar 2024207197
Total6937435308